KalVista’s Ekterly, backed by strong trial data, receives FDA approval as the first oral therapy for acute hereditary angioedema attacks in the US.
FDA Approves KalVista’s Ekterly As First Oral On-Demand Treatment For Rare Swelling Disease
Where Today's News Shapes Tomorrow
